We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+6.45%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$3.23B
AUM Growth
+$1.54B
Cap. Flow
+$1.46B
Cap. Flow %
45.39%
Top 10 Hldgs %
68.77%
Holding
142
New
24
Increased
22
Reduced
20
Closed
25

Top Buys

Rank Stock Value
1
CAVA icon
CAVA Group
CAVA
+$1.32B
2
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$73.7M
3
SLRN
ACELYRIN
SLRN
+$37.2M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$21.3M
5
MORF
Morphic Holding, Inc. Common Stock
MORF
+$17M

Top Sells

Rank Stock Value
1
WW
WW International
WW
+$61.1M
2
ONC
BeOne Medicines Ltd
ONC
+$20.5M
3
FATE icon
Fate Therapeutics
FATE
+$14.8M
4
APLS
Apellis Pharmaceuticals
APLS
+$14.3M
5
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$13.1M

Sector Composition

Rank Sector Weight
1 Healthcare 54.66%
2 Consumer Discretionary 41.39%
3 Technology 0.24%
4 Financials 0.2%
5 Real Estate 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAVA icon
1
CAVA Group
CAVA
$7.57B
$1.31B 40.62%
+32,007,990
New +$1.32B
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$1.04B
$269M 8.34%
117,553,284
+27,775,050
+31% +$73.7M
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$123M 3.8%
2,139,995
+326,046
+18% +$17M
APLS
4
DELISTED
Apellis Pharmaceuticals
APLS
$95.7M 2.96%
1,050,067
-166,245
-14% -$14.3M
XBI icon
5
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$83.2M 2.58%
+1,000,000
New +$83.6M
MRTX
6
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$74.3M 2.3%
2,055,181
+517,472
+34% +$21.3M
ONC
7
BeOne Medicines Ltd
ONC
$34.3B
$73.5M 2.28%
412,496
-88,839
-18% -$20.5M
SRRK icon
8
Scholar Rock
SRRK
$5.92B
$68.3M 2.12%
9,059,507
+31,557
+0.3% +$238K
RVMD icon
9
Revolution Medicines
RVMD
$39.1B
$64.2M 1.99%
2,401,617
+330,629
+16% +$8.11M
FOLD
10
DELISTED
Amicus Therapeutics
FOLD
$57.3M 1.78%
4,562,567
+1,036,160
+29% +$12.3M
CERE
11
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$52.1M 1.61%
1,638,858
-275,608
-14% -$8.46M
SWTX
12
DELISTED
SpringWorks Therapeutics
SWTX
$47.6M 1.48%
1,816,620
-729
-0% -$19.2K
CYTK icon
13
Cytokinetics
CYTK
$10.8B
$46.2M 1.43%
1,416,031
+49,008
+4% +$1.81M
KYMR icon
14
Kymera Therapeutics
KYMR
$8.73B
$41.5M 1.29%
1,805,346
– –
KRYS icon
15
Krystal Biotech
KRYS
$10.7B
$41.1M 1.27%
349,669
-62,413
-15% -$6.37M
SLRN
16
DELISTED
ACELYRIN
SLRN
$38.1M 1.18%
+1,821,214
New +$37.2M
SDGR icon
17
Schrodinger
SDGR
$1.14B
$34.9M 1.08%
700,000
– –
AGEN
18
Agenus
AGEN
$275M
$25M 0.78%
781,562
-14,849
-2% -$475K
DNLI icon
19
Denali Therapeutics
DNLI
$3.82B
$23.7M 0.73%
802,899
– –
SAGE
20
DELISTED
Sage Therapeutics
SAGE
$23.5M 0.73%
500,000
-250,000
-33% -$12.4M
IGMS
21
DELISTED
IGM Biosciences
IGMS
$23.3M 0.72%
2,522,244
+12,272
+0.5% +$137K
KLRS
22
Kalaris Therapeutics
KLRS
$79.5M
$22.4M 0.7%
286,833
+44,347
+18% +$4.22M
KURA icon
23
Kura Oncology
KURA
$826M
$21.4M 0.66%
2,018,056
+300,000
+17% +$3.55M
MLTX icon
24
MoonLake Immunotherapeutics
MLTX
$1.59B
$20.4M 0.63%
+400,000
New +$10.8M
SE icon
25
Sea Limited
SE
$65.8B
$20.3M 0.63%
350,000
+47,500
+16% +$3.39M
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2023 Portfolio in Review

As of Q2 2023, Artal Group held 142 positions worth $3.23B, up 92% from $1.68B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Artal Group deployed $1.46B of net new capital in Q2 2023, opening 24 new positions and adding to 22 existing holdings. Its largest new stake was CAVA Group: 32,007,990 shares worth $1.31B.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 94% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was BeOne Medicines Ltd, an estimated $20.5M trimmed.

  • Artal Group's largest Q2 2023 buy was CAVA Group: 32,007,990 shares worth $1.31B.
  • Artal Group added most to Lexicon Pharmaceuticals in Q2 2023, an estimated $73.7M increase.
  • Artal Group's biggest Q2 2023 reduction was BeOne Medicines Ltd, cutting an estimated $20.5M.
  • Artal Group fully exited WW International in Q2 2023, selling an estimated $61.1M.
  • Artal Group's ten largest holdings make up 69% of its $3.23B portfolio in Q2 2023.
  • Artal Group opened 24 new positions and closed 25 in Q2 2023.
  • Artal Group's portfolio value rose 92% quarter-over-quarter to $3.23B.

Based on Artal Group's 13F filing for Q2 2023, filed 11 Aug 2023.